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Abstract
Background: Tissue plasminogen activator (tPA) is a serine protease involved in fibrinolysis. It is released by
endothelial cells, but also expressed by neurons and glial cells in the central nervous system (CNS). Interestingly,
this enzyme also contributes to pathological processes in the CNS such as neuroinflammation by activating
microglia and increasing blood–brain barrier permeability. Nevertheless, its role in the control of adaptive and
innate immune response remains poorly understood.
Methods: tPA effects on myeloid and lymphoid cell response were studied in vivo in the mouse model of multiple
sclerosis experimental autoimmune encephalomyelitis and in vitro in splenocytes.
Results: tPA-/- animals exhibited less severe experimental autoimmune encephalomyelitis than their wild-type
counterparts. This was accompanied by a reduction in both lymphoid and myeloid cell populations in the spinal
cord parenchyma. In parallel, tPA increased T cell activation and proliferation, as well as cytokine production by a
protease-dependent mechanism and via plasmin generation. In addition, tPA directly raised the expression of MHC-
II and the co-stimulatory molecules CD80 and CD86 at the surface of dendritic cells and macrophages by a direct
action dependent of the activation of epidermal growth factor receptor.
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Conclusions: Our study provides new insights into the mechanisms responsible for the harmful functions of tPA in
multiple sclerosis and its animal models: tPA promotes the proliferation and activation of both lymphoid and
myeloid populations by distinct, though complementary, mechanisms.
Keywords: Tissue plasminogen activator, Neuroinflammation, Experimental autoimmune encephalomyelitis, T cell
response, Antigen-presenting cells
Background
Multiple sclerosis (MS) is a chronic disease of the cen-
tral nervous system (CNS) characterized by lymphoid
and myeloid cell infiltration and microglial activation,
leading to demyelination and progressive neurodegener-
ation [1]. Tissue plasminogen activator (tPA), a serine
protease involved in fibrinolysis [2], is mainly produced
by endothelial cells of vessels [3], whereas this protease
is also secreted by several cell types within the CNS such
as oligodendrocytes [4], astrocytes [5], or neurons [5, 6].
tPA influences neuroinflammatory and neuroimmune
processes [7]. Indeed, its effects are particularly relevant
to the context of MS: tPA activity is increased by tenfold
in the cerebrospinal fluid (CSF) of MS patients [8], and
the protease is found in the perivascular spaces associ-
ated to active MS plaques [9].
Myelin oligodendrocyte glycoprotein (MOG)35-55-in-
duced experimental autoimmune encephalomyelitis
(EAE), a well-established animal model of MS, is charac-
terized by the recruitment and entry of CD4+ encephali-
togenic T cells into the CNS parenchyma [10].
Interestingly, pioneer studies reported that tPA activity
is increased in EAE [11, 12] and that tPA-deficient mice
(tPA-/-) declare EAE later than their wild-type (WT)
counterparts, with less severe symptoms in the early
phase of the disease, reduced demyelination, axonal
damage, microglial activation, and T cell presence in the
parenchyma [11]. Later studies in slightly different ex-
perimental designs drew opposite conclusions, showing
earlier and more severe disease in tPA-/- mice [13]. This
indicates that tPA can provide different effects in the
EAE course, depending on the phase of the disease and
the experimental design.
Several actions of tPA can participate in its controver-
sial effects in EAE. In addition to its protease activity,
tPA exerts various functions due to its five distinct func-
tional domains: finger domain, epidermal growth factor
(EGF)-like domain, kringle 1, kringle 2, and protease do-
main [14]. We have previously shown that tPA, by acti-
vating the EGF receptor (EGFR), has an anti-apoptotic
effect over oligodendrocytes [4] and a chemotactic effect
on their progenitors that helps remyelination after
chemically induced white matter lesions [15]. tPA is also
able to increase blood–brain barrier (BBB) permeability
and helps leukocyte diapedesis [16] by several
mechanisms, including the potentiation of endothelial
N-methyl-D-aspartate receptors (NMDAR) [17] or tight
junction disruption by the modification of occludin
phosphorylation [18]. Our group has shown that Gluno-
mab®, a monoclonal antibody which prevents the binding
of tPA on the GluN1 subunit of NMDAR [19], inhibits
leukocyte entry into the CNS, thus blocking demyelin-
ation and EAE progression [17].
In addition to these actions, controversial data indicate
that tPA may directly act on cells of the innate immun-
ity. tPA can regulate myeloid cell functions, but the pro-
or anti-inflammatory nature of this action is still a mat-
ter of debate [20, 21]. On the other hand, the possible
role of tPA on lymphoid cell activity is still poorly
understood [7]. Therefore, the purpose of this study is to
investigate the respective actions of tPA on lymphoid
and myeloid cells in the context of EAE. Interestingly,
we report a deleterious role of tPA in EAE, that may be
due to an increase in T cell proliferation, combined to a
direct potentiation of dendritic and macrophage antigen
presenting function. These combined effects of tPA con-
verge to the promotion of pro-inflammatory T cell adap-
tive immune response in EAE.
Methods
Animals
Transgenic tPA-/- (C57BL/129 background) [22] and
C57BL/129 control mice, aged 8–12 weeks, were pro-
vided by the Centre Universitaire de Ressources Biologi-
ques (CURB, University of Caen, France). C57BL6/J mice
aged 6–12 weeks were obtained from Janvier Laborator-
ies. Mice were housed in our local conventional animal
facilities. All procedures were performed according to
the guidelines of the institutional ethics committee
(Comité Normand d’éthique en matière d’expérimenta-
tion animale (CeNomExa) and Comité Ético de Experi-
mentación Animal del Hospital Nacional de
Parapléjicos). This was submitted to these committees
for approval in accordance with the European directive
no. 2013/63/UE (agreement number D14118001) and
with the French and Spanish National and Regional
Guidelines for Animal Experimentation and the Use of
Genetically Modified Organisms (French Ministry of Re-
search, project license number 02653.2, Decree 87/848;
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RD 53/2013 and 178/2004, Law 32/2007 and 9/2003,
Decree 320/2010).
Reagents
Recombinant human tPA (Actilyse ®) was purchased
from Boehringer Ingelheim (Ingelheim am Rhein,
Germany). Several controls of tPA and other reagents
were used along the study: dialyzed tPA, tPA GGACK,
or corresponding vehicles (DMSO, Sigma-Aldrich). tPA
dialysis was performed for 48 h at 4 °C against 0.3 M
HEPES to remove the arginine vehicle. tPA GGACK was
obtained by incubating GGACK (1,5-dansyl-L-glutamyl-
L-glycyl-L-arginine chloromethylketone, EMD) with
Actilyse in a fourfold molar excess for 6 h at room
temperature (RT), followed by dialysis for 48 h at 4 °C
with 0.3 M HEPES to remove unbound GGACK and the
arginine vehicle. The loss of proteolytic activity of tPA
GGACK was confirmed with spectrozyme assay (Ameri-
can Diagnostica) [4]. Aprotinin and epsilon-
aminocaproic acid (ε-ACA) were purchased from Sigma-
Aldrich. AG1478 hydrochloride was purchased from
Tocris. Antibodies used in this study are listed in Suppl.
Table 1.
EAE induction
Monophasic EAE was induced in 6–12-week-old
C57BL6/J female and C57BL/129 tPA-/- male mice by
active immunization with MOG35-55 peptide (Cambridge
Research Biochemicals, Genscript). To this end, mice
were injected subcutaneously with 200 μg of Complete
Freund’s adjuvant (Sigma-Aldrich) containing 400 μg of
inactivated particles of Mycobacterium tuberculosis (BD
Biosciences). The emulsion was administered to regions
above the shoulders and the flanks into four sites (50 μL
at each injection site). All animals were intraperitoneally
injected at days 0 and 2 with 250 ng of pertussis toxin
(Sigma-Aldrich) in 200 μL of saline. Mice were weighted
and scored daily in a double blind manner for clinical
signs of EAE as follows: 0, no disease; 1, limp tail; 2,
hindlimb weakness/ no hindlimb reflex; 3, hindlimb par-
esis; 4, hindlimb paralysis; 5, moribund or dead. In ac-
cordance with the ethical standards and regulations, the
humane endpoint criteria were applied when an animal
reached a clinical score of ≥ 4 for more than 48 h or pre-
sented signs of stress or pain (generation of sounds,
stereotypic behavior, lordokyphosis, hair loss, or loss of
weight superior to 2 g/day for more than 48 h).
Isolation of leukocytes from spleens and spinal cords
Mice were deeply anesthetized with 5% isoflurane (Aer-
rane, Baxter) and transcardially perfused with 50 mL of
cold phosphate-buffered saline, pH 7.4 (PBS, Sigma-
Aldrich). Spinal cords were harvested at the EAE plateau
phase [day post-immunization (dpi) 20 ± 3] and
homogenized in PBS. Leukocytes were recovered at the
30:70% Percoll (Fisher Scientific) interface after gradient
centrifugation as described in the literature [23] and
were then counted with the Malassez chamber. Spleens
were aseptically removed from naïve and MOG-
immunized C57BL/6 mice at the peak of clinical score
(≥ 3, dpi 15–18), as described previously [24], mechanic-
ally processed to obtain a splenocyte suspension by pass-
ing the cells through a 40-μm filter (Falcon).
Erythrocytes were lysed in lysis buffer [0.15 M NH4Cl, 9
mM HKCO3, 0.5 M EDTA, pH 7.4 (Stemcell Technolo-
gies)], and the sterile splenocytes were resuspended in
supplemented sterile PBS with 10% filtered and inacti-
vated fetal bovine serum (FBS, Stemcell Technologies),
1% Penicillin/Streptomycin (Gibco), and 2.5% (v/v)
HEPES (Fisher).
Analysis of the effect of tPA on myeloid cell functions
Splenocytes (106 per well in 24 well plates) were cul-
tured and maintained in RPMI (Gibco) supplemented
with 10% FBS (Linus), 1% Penicillin/Streptomycin, 2.5%
(v/v) HEPES, 2 mM L-glutamine (Gibco), and 50 μM β-
mercaptoethanol in the presence of the following mole-
cules for 24 h: tPA (0.2, 2, and 20 μg/mL) or its vehicle
[34.84 mg/mL arginine (Sigma-Aldrich), 10.72 mg/mL
phosphoric acid (Sigma-Aldrich) and 0.1 mg/mL Tween
80 (Sigma-Aldrich)], Glunomab® antibody (10 μg/mL) or
its isotypic control [17], 2 μg/mL tPA-GGACK (with
blocked serine protease activity), 5 μM of the EGFR in-
hibitor (AG1478 hydrochloride, additional 30-min
preincubation).
Analysis of the effect of tPA on lymphoid cell
proliferation
Naive splenocytes (1.5 × 106/mL in suspension) were in-
cubated for 20 min at RT in PBS with 0.5 μM CFSE (Life
technologies). Cells were then washed and suspended in
complete DMEM containing: 1% penicillin–streptomycin
(P/S, Sigma-Aldrich), 1% GlutaMax-I 100X (Gibco), 10%
FBS, and 0.1% β-mercaptoethanol. Ninety six-well U-
bottom plates were coated with 1 μg/mL anti-mouse
CD3 antibody (eBioscience) in PBS overnight. The plates
were washed twice with 200 μL of PBS and 105 labelled
splenocytes were plated (P96 well) in 200 μl of complete
DMEM and incubated for 96 h with 1 μg/mL anti-
mouse CD28 antibody (eBioscience) in the presence or
not of tPA at different concentrations (0.1, 1, and 10 μg/
ml [4], 10 μg/ml Glunomab® antibody or its isotypic con-
trol [17], ε-ACA, an inhibitor of the protease function of
tPA (200 mM), the plasmin inhibitor aprotinin (20 IU/
mL−1) [25], or tPA-GGACK (10 μg/mL). Then, cells
were harvested by centrifugation (2000 rpm, 10 min,
RT), washed in PBS and stained for the flow cytometry
assay. To study the effect of tPA during MOG-induced
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stimulation, splenocytes were obtained from MOG-
immunized C57BL6/J mice at the peak of clinical score
(≥ 3), as described previously [24, 26] and were plated in
IMDM (BioWest, Nuaillé, France), supplemented with
2-mM L-glutamine, 1% P/S, 10% FBS (Gibco), and 50-
μM β-mercaptoethanol, in U-bottom 96-well plates at a
density of 2 × 105 cells. Splenocytes were exposed to 2-
μM Tag-it VioletTM Proliferation and Cell Tracking Dye
(Biolegend) diluted in PBS supplemented with 0.1% BSA
at 37 °C with shaking for 20 min, protected from light.
After washing, splenocytes were stimulated for 72 h with
5 μg/mL MOG and treated with 2 μg/mL tPA, 5 μM
AG1478 or the combination of both. Cells were har-
vested by centrifugation at 2000 rpm at RT, washed in
PBS and stained for the flow cytometry assay.
In order to analyze the direct effect of tPA on MHC-II
upregulation and on T cell proliferation, splenocytes
from EAE mice at the peak of their clinical symptoms
were depleted of CD3 T cells by cell sorting in a FACS
Aria IIu. These splenocytes were plated at 2 × 105 cells
per well in U-bottom 96-well plates with and were ex-
posed to MOG or MOG + tPA. After 24 h, the medium
was replenished in all culture conditions, and 5 × 104
sorted Tag-it Violet-labelled CD3+ T cells from other
EAE mice at the peak of their clinical symptoms were
added to each well. In one of the culture conditions, tPA
was removed to check the direct effect of the protease
on antigen presentation capacity. After 72 h, cells were
harvested, and CD3, CD4, and CD8 proliferative cells
were counted in a FACS Canto II cytometer.
The proliferation index has been calculated dividing
the sum of the cells in all generations by the computed
number of original parent cells, which were theoretically
present at the beginning of the experiment. Analysis of
data was performed using the ModFit LT™ software
(Verity Software House).
Flow cytometry
Cells were resuspended in 50 μl of staining buffer, and
Fc receptors were blocked for 15 min at 4 °C with 10
μg/mL anti-CD16/CD32 antibodies (BD Biosciences.)
After the blocking step, cells were labelled for 20 min at
4 °C with corresponding fluorochrome-conjugated
monoclonal antibodies (Suppl. Table 1). The BD Phar-
mingen transcription factor buffer set was used accord-
ing to the manufacturer’s protocol to detect expression
of FoxP3. When necessary, cells were fixed in a final vol-
ume of 300 μl with 4% paraformaldehyde (PFA) for 10
min. For detection of intracellular cytokines, splenocytes
were stimulated for 5 h with 500 ng/mL PMA (Sigma-
Aldrich) and 500 ng/mL ionomycin (Sigma-Aldrich) in
the presence of 10 μg/ml brefeldin A (Biolegend). Then,
cells were fixed and permeabilized with cyto Fix/Perm
(Biolegend) and stained at RT for 30 min. Samples were
acquired on a FACS Verse or a FACS Canto II cyt-
ometer (Beckton Dickinson), and data were analyzed
with the FlowJo 7.6.5 software (TreeStar Inc.). Cell fre-
quencies were determined by flow cytometry and abso-
lute numbers calculated from counts determined using a
hemocytometer (Malassez chamber).
Cytokine assay
Levels of cytokines in supernatants of anti-CD3/CD28
stimulated splenocytes were determined using the cyto-
metric bead array (CBA) mouse Th1/Th2/Th17 cytokine
kit (BD Biosciences) according to the manufacturer’s
protocol. Measurements were performed using FACS
Verse flow cytometer, and data were analysed with the
FCAP ArrayTM software (version 3.0).
Immunofluorescence
Mice at the EAE plateau phase (d20 ± 3) and with
matching mean scores were deeply anesthetized and
transcardially perfused with 50 mL of cold 1X PBS. Tis-
sue samples were postfixed for 24 h at 4 °C with 4% PFA
and then cryoprotected for 24 h at 4 °C with 20% su-
crose solution, before freezing process into Tissue-Tek
(Miles Scientific). Samples were then cut with a cryomi-
crotome (Leica) to obtain 10-μm sections which were
thaw-mounted on polylysine-coated slides and stored at
– 80 °C before experiment. After warming, sections were
rehydrated three times in PBS during 15 min and incu-
bated overnight at RT with the following antibodies:
rabbit anti-CD3 (1:200, Abcam ab5690), rat anti-CD4 (1:
25, eBiosciences 14-0042-82, clone RM4-5), and goat
anti-colIV (1:1000, Southern Biotech 1340). Primary
antibodies were revealed by using affinipure F(ab’)2 frag-
ments of donkey IgGs conjugated to Alexa 647, Alexa
488 or Cy3 (1:1000, Jackson Immuno Research). Then,
sections were washed in PBS and coverslipped with anti-
fading medium containing DAPI. Images were digitally
captured on Leica DM6000 microscope-coupled cool-
snap camera, visualized with Metavue 5.0 software (Mo-
lecular Devices, USA) and further processed using
ImageJ 1.49e software (NIH). For cell counting, images
of three WT and three tPA-/- hemi-spinal cord sections
from cervical, upper thoracic, lower thoracic, and lum-
bar/sacral regions were analyzed with the Fiji (ImageJ)
software: an image-by-image threshold was applied to
obtain a binary image for automatic particle counting
(cells/mm2) using a minimal particle size assigned to
overcome the background noise of the image.
Statistical analysis
Results are presented as the mean + SEM and were ana-
lysed with the GraphPad Prism and SigmaPlot 11.0 soft-
wares. Normality tests were performed on all samples
(Agostino-Pearson omnibus and Shapiro–Wilk tests).
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Nonparametric Kruskal–Wallis for multiple comparisons
were used, followed by two-by-two comparisons by
Mann–Whitney’s U tests when relevant. For multiple
comparisons, an ANOVA test or its corresponding
ANOVA on RANKS was performed followed by the
Tukey or Dunn post hoc tests (compared with the con-
trol condition or all pairwise), respectively. The mini-
mum value of statistical significance considered was P <
0.05; for comparison of incidence curves, log-rank (Man-
tel-cox test) was used.
Results
EAE is less severe in tPA-deficient mice
tPA-/- mice developed less severe EAE disease than their
WT counterparts (control group), with lower clinical
scores during the plateau phase between dpi 17 and 23
(d20 ± 3) (Fig. 1a). Although no significant difference
was observed between tPA-/- and WT mice in the inci-
dence of the disease (P = 0.1194, Fig. 1b) nor for the day
of disease onset (tPA-/- 15.13 ± 0.88 vs WT 14.6 ± 0.45,
P = 0.8159, data not shown), peak score and cumulative
clinical score were significantly lower in tPA-/- than in
WT mice (tPA-/- peak score 1.16 ± 0.23 vs WT 2.07 ±
0.29, P = 0.0164; cumulative clinical score 10.17 ± 2.89
vs 20.38 ± 3.76, P = 0.0163, Fig. 1c and d). In addition,
severity index ([26]), was significantly lower in tPA-/-
than in WT mice (tPA-/- severity index 0.3440 ± 0.08 vs
WT 0.6652 ± 0.10, P = 0.0075, Fig 1e).
tPA enhances T cell response by a proteolytic mechanism
Given that immune cell infiltration is a cardinal feature of
EAE, we analyzed T cell subpopulations in the spinal
cords of EAE mice during the plateau phase of the disease
(d20 ± 3) by flow cytometry (Fig. 2 and Suppl. Fig. 1) and
immunofluorescence (Suppl. Fig 2). We found that the ab-
solute number of CD4+ T cells was lower in tPA-/- than in
WT mice (6940 ± 1220 vs 27,110 ± 3642 cells; P = 0.0238,
Suppl. Fig 1B, Fig. 2a), an observation consistent with the
clinical scores observed in tPA-/- EAE mice (Fig. 1). Nei-
ther CD8+ (WT 61,291 ± 11,070 cells vs tPA-/- 42,721 ±
4988 cells, P = 0.5476, Fig. 2b) nor regulatory FoxP3+ T
cell (Treg) (WT 2396 ± 2322 cells vs tPA
-/- 394.6 ± 444
cells; P = 0.1667, Fig. 2c) were significantly altered. In ac-
cordance with the above data, CD4+ T cells were the only
CD3+ T cell subset that showed changes in the spinal cord
of tPA-/- mice (tPA-/- 13.87% ± 2.44 vs WT 29.85% ± 4.01,
P = 0.0476, Fig. 2d). Concordantly, the histological analysis
of the spinal cords (Fig. 2e) further showed that the aver-
age density of CD4+ T cells within infiltrated area was
lower in tPA-/- than in WT EAE mice (absolute number
of WT 514.4 ± 135.7 vs tPA-/- 245.3 ± 50.78, P = 0.0495,
Fig. 2g and Suppl. Fig. 2A-C) and that these changes were
mainly due to differences in the cervical region (WT 51.33
± 13.49 vs tPA-/- 9.97 ± 1.98, P = 0.0495, Fig. 2h). Interest-
ingly, when analyzing the cytokine profile of CD4+ T cells
in vivo, we showed that the percentage of IFN-γ/CD4+ T
cells—but not IL-17/CD4+ T cells—was significantly de-
creased in tPA-/- EAE mice as compared with WT EAE
(IFN-γ/CD4+ T cells WT 9.4% ± 4 vs. tPA-/- 2.8% ± 0.8, P
= 0.011; IL-17/CD4+ T cells WT 4% ± 2.3 vs. tPA-/- 2% ±
0.6, P = 0.3; Fig. 2i and j, Suppl. Fig 1C).
To determine the mechanisms involved in the de-
crease of CD4+ T cell number in tPA-/- EAE mice, we
assessed their functional response in vitro after
Fig. 1 tPA-/- mice show less EAE symptoms than WT mice. a Mean EAE clinical score, b incidence, c peak score, d cumulative clinical score, and e
severity index for WT and tPA-/- mice. Results are expressed as mean + SEM. N = 29 (WT) and N = 35 (tPA-/-). *P < 0.05 and **P < 0.01
Hélie et al. Journal of Neuroinflammation           (2021) 18:52 Page 5 of 17
Fig. 2 (See legend on next page.)
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activation with anti-CD3ε/CD28. CD4+ T cells from
tPA-/- naive mice proliferated less than CD4+ T cells
from their WT counterparts (proliferation index: tPA-/-
2.03 ± 0.43 vs WT 6.18 ± 1.38; P = 0.0317; Fig. 3a and
b). Activation level measured by mean fluorescence in-
tensity (MFI) of CD25 was also reduced in CD4+ T cells
from tPA-/- as compared with WT CD4+ T cells (51.42%
± 10.96 of WT; P = 0.0286, Fig. 3d). Importantly, the
addition of exogenous tPA rescued the proliferation and
activation of tPA-/- CD4+ T cells at the same level as
CD4+ T cells from WT counterparts (P = 0.8413 and P
= 0.3143, respectively; Fig. 3a, b, and d). As in the case
of the in vivo analysis, CD8+ T cell proliferation was not
affected in tPA-/- (proliferation index 11.65 ± 4.93 vs
tPA-/- 6.57 ± 3.35, P = 0.3095) although their activation
was reduced (59.34% ± 14.48 of WT, P = 0.0286; Fig. 3a,
c and e).
We next examined the effect of tPA on T cell response
in vitro. tPA significantly increased proliferation and ac-
tivation of anti-CD3ε/CD28 activated CD4+ and CD8+ T
cells in a dose-dependent manner, in comparison with
the control group of untreated cells (Fig. 4a-e). At the
dose of 10 μg/mL of tPA, proliferation of CD4+ and
CD8+ T cells were increased to reach 163.40% ± 11.28
(P = 0.0004) and 170.90% ± 12.59 (P = 0.0012), respect-
ively. No effect of tPA was observed on Treg cells (P =
0.9999, Fig. 4f). In order to further analyze the profile of
CD4+ T cells involved in the response to tPA treatment,
we analyzed by flow cytometry the expression of CCR6
and CXCR3, two chemokine receptors involved in the
CNS trafficking of Th17 and Th1 cells, respectively. We
observed an increase in the percentage of CCR6+/CD4+
T cells, with no changes in the percentage of CXCR3+/
CD4+ T cells after treatment of splenocytes with tPA (10
μg/mL) for 72 h (Fig. 4g).
Next, we investigated the mechanisms underlying tPA
actions on T cells. Since the primary action of tPA is to
activate plasminogen into plasmin, we interrogated the
different elements of the tPA/plasminogen/plasmin cas-
cade. Plasminogen treatment neither increased CD4+ T
cell proliferation nor potentiated the proliferative action
of tPA on CD4+ T cells (P = 0.400 and P = 0.200; Fig.
4h). However, aprotinin, a specific inhibitor of plasmin,
did reverse tPA-mediated activation (for CD4+ T cells, P
= 0.0190; for CD8+, P = 0.0109; Fig. 4i and j). In
addition, the inactivation of the catalytic activity of tPA
(tPA-GGACK) abolished tPA stimulatory effect on
CD4+ and CD8+ T cell proliferation (P = 0.0252 and
0.0162, respectively; Fig. 4i and j). In addition, ε-ACA,
an inhibitor of plasmin generation from plasminogen
inhibited the stimulatory effect of tPA on CD4+ and
CD8+ T cell proliferation (P = 0.0056 and P = 0.0040, re-
spectively; Fig. 4i and j). This indicates that tPA in-
creases T cell proliferation via the proteolytic activation
of plasminogen into plasmin.
We next explored if tPA-mediated effects on T cell
proliferation was related to its previously demonstrated
proteolytic action on NMDAR [27], as this receptor was
previously reported to be expressed on T cells [28, 29].
Glunomab®, a monoclonal antibody that blocks the
interaction between tPA and NMDAR [19], did not alter
the proliferative effect of tPA on CD4+ T cells (Supple-
mentary Fig. 3). This result excluded that tPA may act
on T cell proliferation by acting on NMDAR.
Furthermore, since cytokines are key mediators of T
cell-driven autoimmunity, we analyzed the impact of
tPA on the late cytokine pattern of activated T cells.
tPA-induced an increase of IL-6 and IL-10 secretion by
activated splenocytes at 4 days of culture (respectively
233.9% ± 47.45, P = 0.0289 and 499.4% ± 184.3, P =
0.0029, Fig. 4k). In addition, concerning IL-6, this effect
was not observed with tPA-GGACK and was inhibited
in the presence of ε-ACA or aprotinin (P = 0.0167,
0.0167, and 0.0333, respectively, Fig. 4l). ε-ACA also
reverted the activation of IL-10 secretion by tPA (P =
0.0167, Fig. 4m). Together, these data indicate that tPA
increases T cell proliferation via the generation of plas-
min to increase their proliferation, activation, and secre-
tion of cytokines.
tPA enhances myeloid cell maturation by the activation
of EGFR
Our next step was to analyze whether the distribution of
myeloid cells is altered in the spinal cord of tPA-/- EAE
mice. We found that absolute numbers of CD11c+/
CD11b+ (dendritic cells, DCs) and CD45high/CD11c-/
CD11bhigh (activated microglia and infiltrated macro-
phages, M ) were lower in the spinal cords of tPA-/-
(See figure on previous page.)
Fig. 2 tPA-/- mice show reduced CD4+ T cell infiltration than WT in the spinal cord. Absolute number of infiltrated a CD4+, b CD8+, and c FoxP3+
T cells in spinal cords of WT and tPA-/- EAE mice measured by Malassez cell counting and flow cytometry. Results are expressed as mean + SEM.
N = 6 (WT) and N = 3 (tPA-/-). *P < 0.05. d Percentages of T cell subtypes relative to total CD3+ T cell number in the spinal cord of tPA-/- and WT
EAE mice. e Photomicrographs show representative immunofluorescence staining (from N = 3 for tPA-/-and WT) for CD3, CD4, and COLIV markers
in the lower thoracic region of mice spinal cords. Nuclei were counterstained with DAPI (blue). f Scheme describing the different parts of the
spinal cord. g and h Quantification of the average density of CD4+ T cells within infiltrated areas in g the whole spinal cord and in h individual
segments (Cerv. cervical, Upper Th. upper thoracic, Lower Th. lower thoracic, L/Sacr. lumbar/sacral. (N = 3). *P < 0.05. i and j Intracytoplasmic
cytokine detection by flow cytometry in splenocytes from tPA-/- and WT EAE mice (10 days post-immunization) after stimulation with PMA/
ionomycin. Graphs show the percentage of CD4+/IFN-γ+ T cells and CD4+/IL-17+ T cells. N = 7 (WT) and N = 7 (tPA-/-). **P < 0.01
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EAE mice as compared with their WT EAE counterparts
(DCs 15,474 ± 2984 vs 72,283 ± 8330; P = 0.0238; micro-
glia/M : 14,980 ± 5442 vs 119,228 ± 16,810, P =
0.0238; Suppl. Fig 4, Fig. 5a and b).
We then analyzed whether tPA may affect the propor-
tion and the phenotype of DCs and M (Fig. 6, Suppl.
Fig. 5). First, splenocytes extracted from EAE mice at the
peak of the clinical course were treated with different
concentrations of exogenous tPA (0.2, 2, and 20 μg/mL)
during 24 h. None of the tPA concentrations modified
the percentage of antigen presenting DCs
(CD11c+MHC-II+) and M (F4/80+ MHC-II+) popula-
tions (Fig. 6a and b). However, tPA (2 μg/mL) induced a
significant increase of MHC-II+ MFI in both cell popula-
tions compared to control conditions (DCs 120.75% ±
3.92; M 121.69% ± 4.72, P < 0.001, Fig. 6c and d).
Splenic APCs modify their immunophenotype along the
clinical course of EAE. The number of APCs with a
more immunogenic profile (i.e., MHC-II+ CD80+ CD86+
CD40+ cells) increased along the clinical course of the
disease, being maximum at the peak. In parallel, the
number of APCs with a more tolerogenic immunophe-
notype (i.e., MHC-II+ CD80- CD86- PD-L1+ cells) de-
creased, being minimum at the peak and remained very
high in asymptomatic EAE mice (suppl. Fig. 6). Interest-
ingly, tPA (2 μg/mL) promoted the polarization on the
MHC-II+ expressing antigen-presenting cell (APC) sub-
sets towards a more pro-inflammatory and immuno-
genic phenotype, with a significant increase in the
percentage of MHC-II+ CD80+ CD86+-APCs (DCs
122.45 ± 6.22, P = 0.002; M 128.04 ± 5.70; P = 0.004,
Fig. 6e and f) and a decrease in the percentage of MHC-
II+ CD80- CD86- tolerogenic APCs (DCs 87.09% ± 3.20,
M 86.71% ± 2.70; P = 0.005 and P < 0.001, respect-
ively; Fig. 6g and h).
Then, we aimed at analyzing the receptors and/or tPA
functional domains enrolled in APC maturation. Treat-
ment of APCs with catalytically inactive tPA (tPA-
GGACK) did not modify MHC-II+ expression, although
the difference with native tPA was not significant (tPA:
DCs 121.12% ± 4.211, M 113.96% ± 4.406; P = 0.040
and P = 0,042, respectively, versus control condition;
tPA GGACK: DCs 108.30% ± 4.166; M 105.21% ±
4.647, with respectively P = 0.156 and P = 0.440 versus
control condition and P = 0.072; P = 0.186 versus tPA;
Fig. 7a and b). Nonetheless, none of the tPA-mediated
effects on APC polarization were modified by the
addition of Glunomab® (Suppl. Fig. 7). These data
indicate that the action of tPA on APCs is not mediated
via interaction with NMDAR.
On the other hand, it has been shown that tPA can act
via non-proteolytic “growth factor-like” effects [30],
some of them mediated by its EGF-like domain [4, 15].
The addition of the EGFR blocking agent AG1478 de-
creased MHC-II+ expression on MHC-II+ APCs as com-
pared with the condition with tPA (DCs 55.49% ± 6.525;
M 77.76% ± 2.249; P < 0.001, Fig. 7c and d). These
data indicate that tPA promotes APC maturation partly
by the activation of EGFR.
tPA-mediated APC polarization is accompanied by a
higher MOG-specific T cell response
In order to determine whether the stimulatory effect of
tPA on APC maturation may modify T cell functions,
splenocytes extracted from EAE mice at the peak of the
clinical course were cultured in the presence/absence of
tPA, with or without ex vivo reactivation with MOG. In
the absence of MOG reactivation, tPA by itself did not
induce CD4+ or CD8+ T cell proliferation (CD4+
107.22% ± 10.94; CD8+ 124.73% ± 57.01 data not
shown). Condition with MOG reactivation showed a
higher percentage of proliferation than control condi-
tions for both CD4+ and CD8+ T cells (CD4+ 852.79% ±
125.03; CD8+ 1525.90% ± 261.96, both P < 0.05, data not
shown). Interestingly, tPA potentiated MOG-induced
CD4+ T cell proliferation (132.43% ± 6.28; P < 0.05, Fig.
7e). In line with the previous results about APC matur-
ation, the stimulatory effect of tPA on MOG-activated
CD4+T cell proliferation was abrogated when EGFR ac-
tivity was blocked by AG1478 (81.88% ± 14.25; P < 0.05,
Fig. 7e), while AG1478 did not modify MOG-induced
APC proliferation in the absence of tPA (Fig. 7e). Re-
markably, the stimulatory effect of tPA was not observed
in MOG-activated CD8+ T cells (108.26% ± 5.45; P >
0.05, Fig. 7f), in accordance with what was observed in
the context of CD3/CD28 polyclonal activation of CD8+
T cells extracted from tPA-/- mice (Fig. 3c).
Finally, to assess whether tPA can act directly on
APCs, CD3 T cell-depleted splenocytes isolated from
EAE mice at the peak of the clinical course were stimu-
lated by MOG peptide in the presence/absence of tPA.
After 24 h, Tag-it Violet-labelled sorted CD3 T cells
from the spleen of EAE mice at the peak of the clinical
course were added, and the medium was replenished in
all culture conditions. In one experimental condition,
tPA was removed at 24 h to check the specific effect of
(See figure on previous page.)
Fig. 3 Endogenous tPA stimulates CD4+ T cell proliferation and activation. tPA-/- and WT splenocytes were activated with anti-CD3 and anti-CD28
antibodies (both 1 μg/mL) and treated in the indicated conditions for 4 days. a Representative flow cytometry histograms for proliferation (CFSE)
and activation (CD25+) of T cells. Corresponding quantification of proliferation index for b CD4+and c CD8+ T cells. Percentage of increase of
CD25 for d CD4+ and e CD8+ T cells. Results are expressed as mean + SEM (N = 5). *P < 0.05
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tPA over CD3 T cell-depleted splenocytes. Our data
showed that tPA pretreatment of CD3 T cell-depleted
splenocytes during the first 24 h increased their ability
to potentiate CD4 T cell proliferation (MOG + tPA 24
h: 132.47% ± 3.52; P < 0.05 versus MOG, Fig. 7g). Inter-
estingly, the presence of tPA during the whole experi-
ment did not induce an additional proliferative effect on
CD4 T cells (MOG + tPA 96 h: 136.81% ± 6.22; P < 0.05
versus MOG, Fig. 7g). On the other hand, tPA did not
exert any significant effect on CD8 T cells (MOG + tPA
24 h: 92.55% ± 5.14; MOG + tPA 96 h: 81.55% ± 6.25,
Fig. 7h). These results indicate that tPA can act directly
on APC maturation during the first 24 h of exposition to
potentiate MOG-activated CD4 T cell proliferation.
In sum, our data indicated that the direct and early ef-
fect of tPA on APC maturation and pro-inflammatory
polarization resulted in amplified MOG-induced CD4+
T cell response. This effect may explain the deleterious
role of tPA in EAE.
Discussion
Previous works reported that tPA expression is in-
creased in the CNS during EAE [11, 31], a result
which suggests an involvement of this serine protease
in the EAE physiopathology. Although tPA has been
reported to induce neurotoxic effects [32], these
effects are unlikely to play a significant part in the
processes reported here. In fact, genetically induced
upregulation of tPA expression in neurons does not
impact the score of EAE [31]. Furthermore, the motor
symptoms observed in EAE correlate with both de-
myelination [33] and axonal injury [34] but not with
neuronal death, which is hardly detectable in the
spinal cord of MOG-induced EAE until late stages
[35]. Thus, the pathophysiology of EAE and the tim-
ing of the effects observed in this work, where differ-
ences between tPA-/- and WT mice occur at early
symptomatic stages, also argue against a significant
implication of neuronal death.
Indeed, our study reports a deleterious role of tPA in
EAE by an action on lymphoid and myeloid cell subsets
by two complementary mechanisms: on the one hand,
tPA directly increases T cell activation, proliferation and
IL-6 secretion in a plasmin-dependent manner. On the
other hand, tPA indirectly increases T cell proliferation
by increasing the expression of MHC-II and co-
stimulatory molecules in DCs and M , by both proteo-
lytic and growth factor-like effects. These elements may
bring an explanation to the deleterious effect of en-
dogenous tPA observed here in EAE and put forward
complementary mechanisms of tPA in immune
response.
Fig. 5 tPA-/- mice show reduced myeloid cell infiltration than WT in the spinal cord. Absolute number of infiltrated a DCs and b Mɸ+ activated
microglia in half-spinal cords of WT and KO EAE mice measured by Malassez cell counting and flow cytometry. Results are expressed as mean +
SEM [N = 6 (WT) and N = 3 (tPA-/-)]. *P < 0.05
(See figure on previous page.)
Fig. 4 tPA activates CD4+ and CD8+, but not FoxP3+ T cells in vitro by a proteolytic mechanism. Splenocytes from naive mice were activated with
anti-CD3 and anti-CD28 antibodies (both 1 μg/m) and treated in the indicated conditions for 4 days. a Proliferation estimated by observation
under bright field binocular (left) and representative flow cytometry histograms for CFSE fluorescence (right), indicating the number of cells in
proliferation state at the time of the experiment. Quantification of proliferation index (CFSE) and CD25+ MFI (as index of activation) for b, c CD4+
and d, e CD8+ (N = 4–9). f Quantification of proliferation index for FoxP3+ T cells (N = 3). Proliferation index are expressed as mean + SEM
percentage vs control (Ctrl = 100% baseline). Activation is expressed as mean + SEM percentage of increase of CD25 MFI. g Quantification of
CD4+/CCR6+ T and CD4+/CXCR3+ T cells (N = 4). b–g *P < 0.05, **P < 0.01, ***P < 0.001 vs control. h–j Proliferation index of CD4+ and CD8+ T cells
in the indicated treatment conditions. N = 5–9; *P < 0.05, **P < 0.01, ***P < 0.001 vs control; #P < 0.05 vs tPA. k, l Cytokine measurements
(percentage of control) in activated splenocytes treated in the indicated conditions (N = 4–7). *P < 0.05, **P < 0.01 vs control; #P < 0.05 vs tPA
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Previous data from the literature are contradictory
about the role of tPA in neuroinflammation in EAE.
Some reports indicate that tPA-/- mice present earlier
and more severe disease than their WT counterparts,
suggesting a protective role of tPA [12, 13, 36]. Other
studies using tPA-/- mice, including the present one,
argue for a deleterious effect of tPA [11]. These discrep-
ancies could be explained by different experimental con-
ditions, including different MOG doses, the use of MOG
re-boost or differences in the age of mice, but also in en-
vironmental conditions [37]. These different conditions
determine different EAE severity profiles between la-
boratories, in which the beneficial and deleterious effects
of tPA [38] may then express themselves differently.
Nevertheless, repeated administration of tPA worsened
the clinical scores of EAE and slightly anticipated its on-
set [39], which supports an adverse effect of tPA in this
model. Moreover, our data showing that tPA enhances
IFN-γ, a cytokine with encephalitogenic properties, are
also in favor of a deleterious role of tPA in EAE.
The fact that tPA promotes T cell activation and pro-
liferation is in agreement with recently published data
[36]. The present study provides further elements by
demonstrating that this effect is dependent of plasmino-
gen activation into plasmin. However, the potential
mechanisms downstream of plasmin activation that may
Fig. 6 tPA polarizes splenic APCs from EAE mice towards a pro-inflammatory phenotype. Splenocytes extracted from EAE mice at the peak of the
clinical course were treated in the indicated conditions. a, b Percentage of a CD11c+MHC-II+-DCs and b F4/80+ MHC-II+-Mɸ in each APC
subpopulation. c, d MFI of MHC-II in APCs, e–h Percentage of e, f MHC-II+ CD80+ CD86+ immunogenic and g, h and MHC-II+ CD80- CD86-
tolerogenic APCs in the presence of different tPA concentrations. In all cases, tPA at the concentrations of 0.2 and 20 μg/mL showed no
differences. Results are expressed as mean + SEM (N = 5), *P < 0.05
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act on T cells in the context of EAE remain elusive. At
least three potential candidates can be cited. First, tPA
induces the release of the pro-form of matrix metallo-
proteinase 9 (pro-MMP9) from endothelial cells by acti-
vating the lipoprotein receptor-related protein-1 (LRP)
receptor [40] and activates pro-MMP9 into its active
form, MMP9 via plasminogen activation [41]. Remark-
ably, MMP9 is involved in T cell proliferation, as
MMP9-deficient T cells display altered proliferative
ability [42]. Second, tPA activates heparin-bound EGF
into free EGF, via the action of plasmin and matrix
MMP9, leading to EGFR signalling in different cell types
[43]. Third, plasmin is able to raise the bioavailability of
the chemokine CCL21, known to regulate the homing of
T cells and DCs towards lymphoid organs [44] and to
act as a co-stimulatory molecule to promote T cell ex-
pansion and Th1 differentiation [45]. Interestingly, EGFR
inhibition induces CD4+ T cell anergy in vitro and
Fig. 7 tPA stimulates MOG35–55-dependent APC maturation and T cell proliferation via its EGF-like domain. Splenocytes extracted from EAE mice
at the peak of the clinical course were treated in the indicated conditions. a, b MHC-II MFI in a CD11c+MHC-II+-DCs and b F4/80+ MHC-II+-MΦs
exposed to 2 μg/mL of tPA or 2 μg/mL of tPA-GGACK. c, d Expression of MHC-II MFI in c CD11c+MHC-II+-DCs and d F4/80+ MHC-II+-MΦs after
combined treatment with 2 μg/mL of tPA and 5-μM EGFR inhibitor AG1478. e, f Cell proliferation index of e CD4+ and f CD8+ T cells after
combined treatment with 5 μg/mL MOG35–55, 2 μg/mL of tPA and 5-μM EGFR inhibitor AG1478. N = 6–7 and *P < 0.05, **P < 0.01, ***P < 0.001 vs
control; #P < 0.05, ###P < 0.001 vs tPA. g, h Cell proliferation index of sorted g CD4+ and h CD8+ T cells in co-culture with MOG-stimulated CD3 T
cell-depleted splenocytes with/without 2 μg/mL of tPA during 24 or 96 h (N = 6–7 for a–f, N = 3 for g and h, and *P < 0.05, **P < 0.01, ***P <
0.001 vs baseline; #P < 0.05, ###P < 0.001 vs tPA)
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in vivo [46]. Further experiments may clarify whether
MMP9, EGFR, and/or CCL21 participate in the mecha-
nisms by which tPA promotes T cell proliferation and
activation.
Our data emphasize plasmin-dependent immune func-
tions of tPA in EAE. In accordance with our results,
plasminogen deficiency in mice delays the onset and
protects from demyelination in EAE [47]. Furthermore,
plasmin is able to activate microglia [48], suggesting that
tPA/plasmin axis is an important component to consider
in future studies on the biological mechanisms under-
lying EAE.
Our data show that tPA acts also on myeloid cells by a
distinct mechanism involving EGFR activation. By this
action, tPA increases the expression of MHC-II and the
co-stimulatory molecules CD80 and CD86 by DCs and
M , leading to a polarization from a tolerogenic to an
immunogenic activity state. Our data did not allow to
firmly conclude on a possible implication of the proteo-
lytic activity of tPA in these effects. This possibility
should be more thoroughly addressed in further studies.
Our results were in contrast with a previous study
reporting that tPA reduces macrophage response to LPS
by inhibiting ERK pathway and cytokine production, an
effect mediated via the combined action of NMDAR and
LRP pathways [20]. The mechanisms implied are likely
to be different from what described in the present work:
the increase in antigen-presenting capacity of APCs, in-
duced by tPA, is not prevented by Glunomab®, which
points to the involvement of another pathway. In fact, in
our co-culture system, the CD4 T cell proliferative effect
of tPA on APC is reversed by EGFR inhibition, which in-
dicates that tPA-mediated effects on antigen presenta-
tion are exerted via EGFR activation. The direct EGFR-
mediated effect on T cell proliferation cannot be totally
discarded in light of our observations. Nevertheless, pre-
treatment of T cell-depleted splenocytes with tPA is suf-
ficient to potentiate the proliferation of T cells added
subsequently to the co-culture (Fig. 7g and h). This indi-
cates that tPA-mediated effects on antigen presentation
are directly exerted via EGFR and essentially mediated
via an action on APCs. Our study is the first that corre-
lates the expression of MHC-II molecules with the acti-
vation of EGFR by tPA. However, the downregulation of
MHC-II expression by AG1478 in the absence of tPA
may indicate that EGFR is intrinsically involved in anti-
gen presentation. Interestingly, EGFR downstream sig-
nalling inhibition is a promising strategy in diverse
tumor types by inducing MHC-II in APCs and breaking
down tolerance [49]. Our data reinforces the idea of tar-
geting EGFR activity as an interesting target to modulate
MHC-II expression, either to potentiate it, as in the case
of cancer, or to reduce it, as in the case of MS or other
autoimmune diseases in which tolerance induction is
one of the golden aims in cell therapy-based strategies
[50].
These data show that tPA can act on the myeloid
population by mechanisms independent of plasmin gen-
eration and complete previous reports showing that tPA
can activate microglial cells via its finger domain
through annexin II [30]. In order to gain insights into
the primary target cells of tPA action in EAE, further
studies may be conceived. For instance, passive EAE ex-
periments may be induced with encephalitogenic T cells
that would be treated with tPA prior to adoptive
transfer.
tPA-induced enhancement of IL-6 cytokine production
by activated splenocytes is also in favor of a pro-
inflammatory role of tPA in EAE. Indeed, this cytokine
is crucial for neuroinflammation as illustrated by the fact
that IL-6-deficient mice are resistant to EAE [51]. How-
ever, tPA also intriguingly increases IL-10 production, a
cytokine with immunomodulatory functions. However, it
should be kept in mind that IL-10, as many cytokines,
may have dual effects depending on the context. For ex-
ample, IL-10 may have immunostimulating properties by
promoting the generation of cytotoxic T cells [52] and
NK cells [53], or favoring the germinal center response
[54]. So, further works are needed to explore the net ef-
fect of tPA on the cytokine network and neuroinflamma-
tion in the course of EAE.
Conclusion
Our study opens new clues into the mechanisms by
which tPA/plasmin axis participates in the pathogenesis
of MS and its animal models. These mechanisms could
be involved also in other neurological diseases such as
Alzheimer’s disease, amyotrophic lateral sclerosis and
Parkinson’s disease in which T cells are also involved
[55]. Our study paves the way for further studies investi-
gating the downstream targets involved in the proin-
flammatory effects of tPA in T cells and myeloid cells.
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Additional file 1: Suppl Figure 1: Gating strategy and lymphoid
cell response after EAE in WT and tPA-/- mice. (A) Representative
gating strategy for absolute cell count analysis of leukocyte subsets in
spinal cord homogenates (WT mouse, plateau phase of EAE). (B) CD3+
leukocytes were gated for subpopulation analysis after using scattergram
gates for viable leukocytes (in A). (C) representative flow cytometry plots
for the assessment of intracellular cytokines IFNγ and IL-17 in CD4+ cells
after EAE in WT and tPA-/-. Suppl Figure 2: T cell infiltration in the
spinal cord of WT and tPA-/- EAE mice. Photomicrographs show rep-
resentative images (from N=3) of indicated markers in spinal cord tissue
samples of WT and tPA-/- mice at the EAE plateau phase (d20±3) from
(A) cervical, (B) upper thoracic, and (C) lumbar sacral. Suppl Figure 3:
Glunomab does not prevent the effect of tPA on T cells. Spleno-
cytes activated with both anti-CD3ε and anti-CD28 antibodies were
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treated or not with tPA at 10 μg/mL in presence of Glunomab or the iso-
typic antibody for 4 days. Proliferation index (%) of (A) CD4+ and (B)
CD8+ T cells in the indicated conditions. Results are expressed as mean +
SEM (N=3). *P<0.05 vs control #P< 0.05 vs indicated experimental group.
Suppl Figure 4: Myeloid response of WT and tPA-/- mice at the
plateau phase of EAE. Representative gating strategy for absolute cell
count analysis of leukocyte subsets in spinal cord homogenates of WT
and tPA-/- mice. CD3- leukocytes were gated for subpopulation analysis
after using scattergram gates for viable leukocytes (see Suppl.fig 1A).
Suppl Figure 5: Myeloid response to tPA treatment. Representative
flow cytometry plots for (A) dendritic cells and (B) macrophages after
tPA treatment (0-20 μg/mL). Suppl Figure 6: Dynamic modification
of immunogenic and tolerogenic DC phenotype along the EAE
clinical course. CD40 is highly present at the moment of maximum af-
fectation and decreased when symptoms partially recover. PD-L1 is in-
creased after the recovery of the clinical symptoms. Asymptomatic
immunized mice showed a high presence of PD-L1+ tolerogenic DCs.
C.S= clinical score and d.p.i= day post-immunization. Suppl Figure 7: Ef-
fect of tPA on APC maturation is not mediated by its ability to
interact with NMDA receptor. Splenocytes extracted from EAE mice at
the peak of the clinical course were treated with 2 μg/mL tPA in pres-
ence of Glunomab or an isotypic antibody (A-H). The percentages of
MHC-II+CD80+CD86+ immunogenic and MHC-II+CD80-CD86- tolerogenic
APCs were determined by flow cytometry. Results are expressed as mean
+ SEM (N=5); *P< 0.05, **P<0.01 and ***P<0.001.
Additional file 2: Suppl. Table 1: Antibodies used in the present study.
Each antibody is indicated with its target antigen, host species, clone
number, isotype and commercial reference
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